333 results about "Cell growth" patented technology

Disclosed in the present invention are a gel having a regulatable free water content and morphology, a preparation method therefor, and the use thereof. The method comprises: S1, preparing a solution A from a natural polymer material; S2, mixing a small molecule material containing a positively charged polar group with the solution A to obtain a composite solution B; S3, mixing the composite solution B with a regulator to obtain a composite solution C, stirring same, then adding a condensing agent to the reaction system, and carrying out a curing crosslinking reaction; and S4, removing the regulator and the condensing agent to obtain the gel. By adjusting the concentrations of the natural polymer material and the regulator, gels having different morphologies can be prepared; the gel undergoes a physical process to remove hydrogen bond interaction between the gel and free water, so that the content of free water attached to the surface of the gel can be regulated, thereby regulating the physical and chemical properties of the gel. The gel of the present invention has regulatable morphology and controllable elastic modulus, and has many advantages such as good lubrication effect, good biocompatibility and biodegradability, capability of being biologically active, and capabilities of stimulating cell growth and accelerating wound repair.

Methods, compositions and uses for inhibiting the growth in blood cancer cells in a patient with one or more of a caffeic acid phenpropyl ester (GL8) analogue selected from the group consisting of As26, J229, J91, LL27, LL23, HM7, As25, MT26, and J205. The blood cancer cells can be myeloma, lymphoma and leukemia cells. The methods, compositions and uses can be in conjunction with the use of an IMiD to treat a patient. The compositions can include a pharmaceutically acceptable carrier, adjuvant or vehicle, a pharmaceutically acceptable salt or dietary supplement.

The invention discloses a physiological microenvironment-based cell culture simulation system, which relates to the field of cell culture, and comprises a main control unit adopting an embedded microcontroller; the multi-mode environment simulation unit is connected with the main control unit and comprises a fluid shear force module and a mechanical stretching module; the multi-parameter environment monitoring unit is connected with the main control unit and comprises an optical sensor for monitoring cell density, a pH sensor for monitoring environment parameters and a temperature sensor; the culture chamber is used for accommodating a cell culture; the environment regulation and control unit is used for regulating culture environment parameters; the multi-modal environment simulation unit and the multi-parameter environment monitoring unit are integrated, and the main control unit optimizes a multi-target control strategy in a manner of dynamically adjusting a weight coefficient based on cell growth state parameters monitored in real time, so that accurate and adaptive closed-loop management of cell culture is realized.

The invention relates to an extraction and culture method of urine-derived stem cells, and belongs to the field of cell biology and regenerative medicine. The method comprises the following steps: coating a culture plate with a gelatin solution; collecting clean midstream urine of healthy people and adding antibiotics; centrifugally separating the cell precipitate; washing with a phosphate buffer solution; re-suspending the precipitate by using a urine stem cell complete culture medium for primary culture; and after the cells grow to a certain fusion degree, carrying out passage amplification. The urine stem cell complete medium comprises a basic medium, fetal calf serum, epidermal growth factors, platelet-derived growth factors and basic fibroblast growth factors. By adopting the method disclosed by the invention, the urine-derived stem cells can be efficiently and stably separated from urine, and the obtained cells have high multiplication capacity, good stemness maintaining capacity, multidirectional differentiation potential and immunoregulation function, and can provide an ideal seed cell source for treating diseases such as diabetic erectile dysfunction.

The invention discloses application of beta-nicotinamide mononucleotide in regulation and control of gene editing efficiency, belongs to the field of gene editing treatment, and finds that the beta-nicotinamide mononucleotide (NMN) can efficiently inhibit the activity of CRISPR-Cas9, CRISPR-Cas12 and CRISPR-Cas13 systems in a broad-spectrum manner for the first time. The application comprises emergency blocking of off-target effect in gene editing clinical treatment, biological safety prevention and control of a virus vector gene editing system, and CRISPR activity regulation and control of in-vitro non-diagnostic purpose. Experiments show that NMN can inhibit CRISPR-mediated gene damage and cell death in a cell model, the inhibition efficiency in an in-vitro enzyme digestion system reaches 68.7%, and cell growth or transfection efficiency is not affected. The invention provides an innovative solution for safe application of CRISPR (clustered regularly interspaced short palindromic repeats) technology, and the NMN is approved to be taken orally as a health care product, so that the NMN has extremely strong clinical application potential. Compared with the existing CRISPR (clustered regularly interspaced short palindromic repeats)-resistant protein or synthetic small-molecule inhibitor, the NMN has the advantages of endogenous property, high biocompatibility, good oral safety and the like.

The application belongs to the technical field of biological medicine, and provides application of an NTSR1 inhibitor in preparation of a drug for enhancing the anti-tumor effect of a PD-1 monoclonal antibody, which is combined application of the NTSR1 inhibitor SR48692 and the PD-1 monoclonal antibody in preparation of a drug for treating lung cancer. The application establishes a subcutaneous lung cancer mouse model and a subcutaneous melanoma mouse model, and evaluates the growth inhibition effect of SR48692 on the two kinds of tumor cancer cells; the result shows that the NTSR1 inhibitor SR48692 can achieve the purpose of treating lung cancer and melanoma by inhibiting the growth of cancer cells.

The application discloses a kind of live cell dynamic monitoring method, comprising the following steps: obtaining the cell scanning picture group that live cell grown in culture vessel is photographed under specified condition, and the picture is preprocessed;Cell scanning picture group after pre-processing is input into trained cell identification model, and output cell growth state chart group;Cell growth state chart group is input into trained survival rate calculation model, and the survival rate of cell in each cell growth state chart is output;The cell survival rate numerical value obtained is drawn into cell survival rate-time curve chart;The cell survival rate-time curve chart generated is combined with nonlinear regression statistical method, and the half inhibitory concentration value of the efficacy of specified parameter calculation is selected.The growth state of cell under specified condition is monitored, and the survival rate of cell and the half inhibitory concentration value of the efficacy are calculated based on these data;It can significantly improve the efficiency and accuracy in the field of drug research and development, drug screening, treatment scheme effect, etc.

This invention relates to the fields of bioengineering and fermentation engineering, and discloses a genetically engineered *Streptomyces albopictus* strain that produces high levels of ε-polylysine and its fermentation production process. This genetically engineered strain uses *Streptomyces albopictus* strains acclimated to ε-polylysine tolerance as a chassis, and its genome integrates... ppc and dapf Through expression box, heterogeneous asd Expression cassettes, containing secretory signal peptides lysp Fusion expression cassettes and D404A / K499A point mutations pls Expression cassette. The fermentation process employs a two-stage pH control strategy, maintaining a neutral environment during the cell growth phase and adjusting to an acidic environment during product synthesis. This invention improves ε-polylysine yield through a synergistic strategy of enhancing precursor supply, constructing efflux detoxification channels, and increasing synthase activity; combined with an acidic fermentation process, it effectively inhibits product degradation, yielding a high-molecular-weight and highly uniform target product suitable for industrial production.

This invention relates to the fields of microbial genetic engineering and fermentation biomanufacturing technology, specifically disclosing a recombinant Corynebacterium glutamicum with high 5-aminolevulinic acid (ALA) production and its applications. Addressing the problems of existing strains such as crude enzyme activity regulation, inhibited cell growth, the need for external inhibitors, and low yield, this invention uses Corynebacterium glutamicum as a host and removes the gdhA gene without scarring to reduce precursor competitive metabolism. Site-directed mutations of the endogenous hemB gene (S288A, D128E, R231K) are performed to moderately reduce dehydratase activity. A high-expression plasmid pXMJ19-hemA containing the hemA gene from Rhodopsinus capsulatum is constructed and introduced into the modified strain to obtain a recombinant strain with optimized triple metabolism. This strain reduces product degradation without the need for external dehydratase inhibitors, does not affect cell growth, and achieves a yield up to 4.30 times higher than the control after 42 hours of fermentation, with ALA accumulation exceeding 8.9 g / L. The strain exhibits stable characteristics, the process is simple, and it has good industrial application value.

The invention belongs to the technical field of gene engineering, and particularly relates to a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of AML patients and application of ubiquitin specific protease 20 serving as a target spot in treating acute myelogenous leukemia. The invention provides a medicine for treating AML (acute myelogenous leukemia) and / or prognosis of an AML patient and application of ubiquitin specific protease 20 as a target spot in treating acute myelogenous leukemia, USP20 is used as a super enhancer regulation gene, and the progress of the AML is promoted by combining with CTNNB1, ERG, ELF1 and RUNX1. The knock-down of the USP20 can significantly inhibit AML proliferation in vivo and in vitro. The wnt-beta-catenin pathway can be influenced by interfering the expression of the USP20 so as to influence the progress of AML (acute myeloid leukemia). And the inhibition effect of the inhibitor AS1517499 subjected to virtual screening on the growth of the AML cells is superior to that of a commercial inhibitor GSK2643943A of USP20.

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

Systems and methods for encapsulating cells in hydrogel tubes for cell growth within hydrogel tubes are described. In aspects, a system includes a plurality of peristaltic pumps and a plurality of pulse dampeners to provide oscillatory-controlled flow rates of each of a cell solution, a hydrogel solution, and a cross-linking solution to an extruder configured to form hollow hydrogel tubes having suspended biological cells in an interior

The subject matter of this specification can be implemented in, among other things, methods, systems, computer-readable storage medium. A method can include receiving cell growth data with a current cell culture of a cell growth system. The cell growth data includes growth input parameter values indicative of a growth rate of the current cell culture. The method can further include identifying, using a first machine learning model, a prescriptive action to alter a yield of a target product of the current cell culture based on the cell growth data. The prescriptive action modifies a metabolism rate of the current cell culture. The method further includes performing at least one of displaying the identified prescriptive on a graphical user interface (GUI) and / or causing the cell growth system to perform the identified prescriptive action.

The utility model discloses an angle-adjustable rotary tank type mesenchymal stem cell balling device, which relates to the technical field of mesenchymal stem cell balling, is arranged in a temperature control incubator for culturing mesenchymal stem cell balling, and comprises a bottle body for containing mesenchymal stem cells and a container for containing ultrasonic buffer water, the container is fixedly arranged on a horizontal bearing surface in the temperature control incubator, the bottle body is obliquely arranged, the bottom of the bottle body is positioned in the ultrasonic buffer water liquid of the container, the bottle body is driven to move by a driving device fixed on the horizontal bearing surface, and the driving device is configured to enable the bottle body to vibrate back and forth in the container along the horizontal direction and simultaneously drive the bottle body to move back and forth. And the bottle body also rotates around the axial direction of the bottle body. According to the utility model, the culture bottle simultaneously performs compound motion of horizontal oscillation and self rotation, so that the cell growth can be more uniformly stimulated, and the problem of poor balling effect caused by single rotation in the traditional method is solved. Through the movement mode, the cells are distributed more uniformly in the culture solution, and the formed spheres are more consistent in size and higher in quality.

The present invention provides an agent for protecting and regenerating pancreatic beta cells in a mammal having diabetes, the agent containing a recombinant viral vector that expresses hepatocyte growth factor (HGF), wherein the agent is characterized by being administered in a dose of 1010-1012 virus particles (vp) / kg body weight, and by the virus vector including a nucleic acid that encodes HGF downstream of a promoter having transcription activity capable of yielding a therapeutically effective HGF level in the blood at said dose.

The application provides a combination drug of a PLA2G7 inhibitor and a chemotherapeutic drug and its use in resisting triple-negative breast cancer, and belongs to the technical field of medicines. The combination drug is a PLA2G7 inhibitor and a chemotherapeutic drug in the same or different specifications of unit preparations for simultaneous or separate administration, and a pharmaceutically acceptable carrier. The application first discovers and proves that the PLA2G7 inhibitor Darapladib can significantly enhance the anti-tumor activity of paclitaxel, 5-fluorouracil or cisplatin on triple-negative breast cancer, and meanwhile, the combination of the PLA2G7 inhibitor and paclitaxel has a synergistic effect in down-regulating the phosphorylation level of STAT3 protein in cancer cells and inhibiting the growth and proliferation of cancer cells; the combination of the PLA2G7 inhibitor and 5-fluorouracil also shows a synergistic effect in inhibiting the growth and proliferation of cancer cells. The application provides a new and effective combination drug strategy for improving the treatment effect of the chemotherapeutic drug on triple-negative breast cancer.

This invention discloses a *Bacillus laterosporus* strain for the stable production of nonribosomal cyclic lipolipeptide and its construction method. The M1A gene in the Bogorol biosynthetic gene cluster is knocked out using CRISPR-Cas9 technology to block the Bogorol pathway, which competes with Brevicidine for substrates. Subsequently, the pMCCas9-S48 plasmid, which integrates S8 and S41 sgRNAs and their homologous arms as repair templates, is used to simultaneously knock out S8 and S41 family peptidase genes, preventing the expression of extracellular degradation enzymes. This invention also provides the application of the above strain in the preparation of nonribosomal cyclic lipolipeptide of Brevicidine and a method for preparing the nonribosomal cyclic lipolipeptide. This strain, through reducing metabolic competition and preventing product degradation, exhibits rapid cell growth, stable production of Brevicidine, and significantly reduced degradation rate, resulting in a 66.13% increase in fermentation yield compared to the unmodified strain. This invention solves the problems of degradation and unstable yield in the production of Brevicidine, provides an effective technical approach for the industrial production of Brevicidine, and provides important technical support for the development and application of novel antimicrobial peptide drugs.

This invention discloses a firming and wrinkle-reducing eye cream, comprising a moisturizer, a whitening agent, a skin repair additive composition, a thickener, a preservative, a film-forming agent, a skin moisturizer, and a surfactant. The weight ratio of the moisturizer, whitening agent, anti-aging additive composition, thickener, preservative, film-forming agent, skin moisturizer, and surfactant is 20:1:2:3:0.3:0.5:1:0.2. The moisturizer includes butylene glycol, glycerin, polydimethylsiloxane, and hydrogenated polyisobutylene. The skin-repairing additive composition includes hydroxypropyl tetrahydropyranotriol, adenosine, cell growth factors, ceramides, and salicylic acid, comprising olefins, betaine, trehalose, 1,2-hexanediol, hydrogenated lecithin, allantoin, and Euglena galactosides. The film-forming agents include polyacrylamide, cyclohexylsiloxane, and polydimethylsiloxane alcohol. The emollients include C13-14 isoparaffins, polydimethylsiloxane / vinyl dimethylsiloxane crosspolymers, and cyclopentamethoxysiloxane. This invention can repair cells and provide long-lasting anti-wrinkle and whitening protection for the corners of the eyes.

The present disclosure relates to novel compounds that act as modulators of cereblon (CRBN). The compounds promote CRBN-mediated ubiquitination and proteasomal degradation of oncogenic proteins such as GSPT1 and MYC, thereby suppressing abnormal cell growth. Pharmaceutical compositions containing the compounds and methods of using the compositions for the treatment of cancers, particularly solid tumors, are also provided.

The present invention relates to a peptide binding to OTUB1 and a use thereof. A peptide of a specific sequence having the property of binding to OTUB1 is observed to exhibit an anticancer effect on cancer cells without affecting the cell growth of normal cells, and thus can be usefully used as a composition for preventing, treating, or alleviating cancer diseases.

The invention discloses a multi-source time sequence image analysis method and system based on cell growth fusion evolution, and the method comprises the steps: S1, obtaining multi-source time sequence image data, and constructing a time sequence image sequence under a unified time axis; s2, the two-dimensional image at each moment is divided into m space patches, multi-dimensional response representation is constructed, and a time sequence feature description set is formed; s3, constructing a multi-layer confidence evolution model, introducing growth confidence, fusion confidence, uncertainty confidence, an evolution stability factor and a global evolution potential function, and performing joint modeling on a co-evolution relationship of a growth state and a fusion state in a time dimension; and S4, constructing a multi-target joint optimization function for fusion degree evaluation, carrying out weighted optimization on various losses, and outputting fusion degree estimation values, fusion stage judgment results and structure evolution description information corresponding to the multi-source time sequence images at the time nodes. The method has the advantages of high analysis stability, high applicability and the like.

A method of inhibiting a cancer cell growth includes contacting the cancer cell with a Cu2(OH)3NO3 / CaSiO3@g-C3N4 nanocomposite material containing graphitic carbon nitride (g-C3N4), copper hydroxide nitrate (Cu2(OH)3NO3) and calcium silicate (CaSiO3), achieving an inhibition efficiency on human breast carcinoma (MCF-7) and human hepatocellular carcinoma (HepG-2) cell growth of greater than 95% in an in-vitro cellular viability assay.

The present disclosure relates to the use of a maltose dependent degron to control stability of a protein of interest fused thereto at the post-translational level. The present disclosure also relates to the use of a maltose dependent degron in combination with a maltose-responsive promoter to control gene expression at the transcriptional level and to control protein stability at the post-translational level. The present disclosure also relates to the use of a stabilization construct that couples expression of a cell-growth-affecting protein with the production of non-catabolic compounds. The present disclosure further relates to the use of a synthetic maltose-responsive promoter. The present disclosure further provides compositions and methods for using a maltose dependent degron, a maltose-responsive promoter, and a stabilization construct, either alone or in various combinations, for the production of non-catabolic compounds in genetically modified host cells.

The present invention belongs to the technical field of sensorineural hearing. Provided is the use of SPTBN1 as a target in the treatment of GJB2-related sensorineural hearing loss. The use comprises: the construction of a stably transfected cell line, wherein: HEK293T cells are cultured using a DMEM culture medium supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin in a humidified incubator at 37ºC with 95% air and 5% CO2, and when the cells reach 80%-90% confluence, cell passage is performed; IP-MS analysis, wherein: protein complexes are purified using Protein A / G immunoprecipitation magnetic beads, a portion of the extracted proteins is used as input, and then 2 μg of anti-Cx26 antibody is added to the remaining protein extract, same are gently pipetted and mixed, and incubated on a rotating shaker at 4℃ overnight; immunofluorescence observation of the co-localization of Cx26 and SPTBN1, wherein: a stably transfected cell line expressing WT-Cx26 and Mut-Cx26 is constructed; and co-immunoprecipitation (Co-IP) validation, wherein: a stably transfected cell line expressing WT-Cx26 is constructed. The present invention overcomes the limitations of therapeutic methods, such as the relatively low targeting specificity and short therapeutic time windows associated with full-length protein supplementation via gene therapy, thereby providing new insight into GJB2-related hearing loss, and a new target and a new treatment for same.

A microcavity bioreactor is provided that allows cell growth and cell differentiation in the same vessel, such that higher order three-dimensional cell cultures such as organoids can be generated in a singular vessel. The microcavity bioreactor may be part of a microcavity bioreactor system that allows for perfusion based cell culture and perfusion based cell harvesting. The microcavity bioreactor includes at least one, and preferably at least two, fluid distributor structures in the housing vessel of the microcavity bioreactor.

The present invention generally pertains to methods of cultivating cells and producing a recombinant protein of interest, such as dupilumab. In particular, the present invention pertains to the use of a fixed seed schedule to determine the expansion time of seed train unit operations for improved cell growth and protein titer. The protein produced by the fixed seed schedule, such as dupilumab, can be later subjected to lipase activity reduction methods.

The invention belongs to the technical field of tumor drugs, and provides application of timosaponin A1 in treatment of colorectal cancer, and the application is that timosaponin A1 is applied to preparation of drugs for treating colorectal cancer. The inhibition effect of timosaponin A1 on mitochondrial activity in colorectal cancer cells is evaluated through in-vitro cell experiments, two mouse tumor models, multi-omics analysis and other methods; results show that timosaponin A1 can stabilize a DHRS4-LONP2-TFAM compound in vivo and in vitro, so that TFAM degradation is promoted, mitochondrial biogenesis is inhibited, tumor cell growth is inhibited, and the aim of treating colorectal cancer is achieved.

The invention discloses a construction method of a synovial sarcoma tumor ball vascular induction model, the model and application of the synovial sarcoma tumor ball vascular induction model. The construction method of the synovial sarcoma tumor sphere vascular induction model comprises the following steps: S1, suspension culture of synovial sarcoma organs; and S2, constructing a synovial sarcoma tumor ball vascular induction model based on the culture chip. When the synovial sarcoma organ is cultured, the synovial sarcoma primary tissue is cultured in a suspension culture mode, and the method not only can improve the proliferation speed of the synovial sarcoma organ, the cell growth state is better, the activity is higher, but also has the advantage of simplicity in operation. Besides, the synovial sarcoma tumor sphere vascular induction model is constructed based on the culture chip, and the model can simulate tumor microenvironment more truly, has tumor-related fibroblast and vascular components, and provides more clinical drug sensitivity test results.

An automated system for signaling cell growth events using continuous sensor data includes at least one sensor associated with a vessel configured for use in growth of cells, the sensor providing continuous sensor data associated with cell growth, a reader in operative communication with the sensor to collect the continuous sensor data, and a computational unit operatively connected to the reader, wherein the computational unit is configured to receive as input the continuous sensor data and calibration data associated with process conditions, the computational unit further configured to perform signal processing on the continuous sensor data in order to predict at least one of future critical events and generate insights about unexpected behavior.

The present application relates to a method for preparing and expanding a TSCM cell in vitro. Specifically, the method comprises: 1) obtaining an isolated CD8+ T cell; 2) activating the CD8+ T cell; 3) mixing the activated CD8+ T cell, a fibrinogen solution and a thrombin solution, and culturing same under conditions suitable for cell growth, so as to obtain a TSCM cell culture; and 4) bringing the culture into contact with a dispase so as to obtain a TSCM cell. The present application also relates to a kit for preparing and expanding a TSCM cell in vitro, the use of fibrinogen and thrombin in the preparation of a kit for preparing and expanding a TSCM cell in vitro, and a TSCM cell obtained by means of the method or kit of the present application.